Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Compass Therapeutics, Inc. (CMPX : NSDQ)

• Company Description    Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based in Boston, MA. Number of Employees: 35

• Price / Volume Information    Yesterday's Closing Price: $2.62 Daily Weekly Monthly 20 Day Moving Average: 890,538 shares Shares Outstanding: 138.28 (millions) Market Capitalization: $362.30 (millions) Beta: 1.48 52 Week High: $4.08 52 Week Low: $0.77 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.74% 15.76% 12 Week 49.71% 31.19% Year To Date 80.69% 70.66%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 80 GUEST STREET SUITE 601 - BOSTON,MA 02135 USA ph: 617-500-8099 fax: - ir@compasstherapeutics.com http://www.compasstherapeutics.com

• General Corporate Information    Officers Thomas J. Schuetz - Chief Executive Officer Carl L. Gordon - Chairman Barry Shin - Chief Financial Officer Neil Lerner - Chief Accounting Officer Phil Ferneau - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 20454B104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 138.28 Most Recent Split Date: (:1) Beta: 1.48 Market Capitalization: $362.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.50 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.29 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -50.00% vs. Previous Quarter: -9.09% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -42.47 12/31/24 - -34.84 ROA 06/30/25 - - 03/31/25 - -38.31 12/31/24 - -32.57 Current Ratio 06/30/25 - - 03/31/25 - 8.33 12/31/24 - 14.96 Quick Ratio 06/30/25 - - 03/31/25 - 8.33 12/31/24 - 14.96 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -6,496.59 12/31/24 - -5,808.82 Book Value 06/30/25 - - 03/31/25 - 0.80 12/31/24 - 0.91 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©